002022 科华生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-1.280-5.20722.36624.25124.567
总资产报酬率 ROA (%)-0.784-2.99512.31813.15213.951
投入资产回报率 ROIC (%)-1.008-4.12917.64318.12918.417

边际利润分析
销售毛利率 (%)40.42642.34752.55754.54458.292
营业利润率 (%)-4.666-7.38629.63033.81532.663
息税前利润/营业总收入 (%)-3.447-7.12228.48034.65533.474
净利润/营业总收入 (%)-4.128-7.28924.85327.88927.487

收益指标分析
经营活动净收益/利润总额(%)148.14857.831105.58198.313101.451
价值变动净收益/利润总额(%)-18.657-13.1510.189-0.1200.106
营业外收支净额/利润总额(%)3.2593.384-0.001-0.250-0.092

偿债能力分析
流动比率 (X)4.9544.7803.1394.8373.183
速动比率 (X)3.7203.7002.5234.0042.581
资产负债率 (%)26.39726.78633.63726.22434.768
带息债务/全部投入资本 (%)19.38617.69818.07819.02427.789
股东权益/带息债务 (%)402.896448.473438.286412.404254.239
股东权益/负债合计 (%)231.755228.795162.327212.308151.144
利息保障倍数 (X)-2.506-13.635-24.76537.51839.812

营运能力分析
应收账款周转天数 (天)220.158178.21058.71966.21563.963
存货周转天数 (天)331.624288.244113.936129.263135.211